Last reviewed · How we verify
NCT07282158
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
NA trial testing Behavioral Intervention in Ovarian Carcinoma in 25 participants. Currently enrolling.
31 December 2029
Quick facts
| Lead sponsor | Fred Hutchinson Cancer Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 25 |
| Start date | 1 May 2026 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Behavioral Intervention
- Interview
- Survey Administration
Conditions studied
- Ovarian Carcinoma — all drugs for Ovarian Carcinoma →
- Psychiatric Disorder — all drugs for Psychiatric Disorder →
Sponsor
Fred Hutchinson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Ovarian Carcinoma or Psychiatric Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial tests an adapted version of the Helping Ovarian Cancer Patients Cope (HOPE) intervention to address burnout among gynecologic oncology clinicians. Stress and burnout among gynecologic oncology clinicians can have far-reaching impacts not only on physicians at the individual level (e.g., distress, mental illness) but also at the professional (e.g., worse patient outcomes, increased errors) and societal levels (fewer physicians in this specialty, more system strain). The original Helping Ovarian Cancer Patients Cope (HOPE) is a workshop to promote hope among patients with ovarian cancer through creating positive narratives using the hope theory and social-cognitive theory. The adapted intervention for clinicals (HOPE-C) will use the same concepts but tailored to clinician experiences by fostering peer support and retelling their challenging stories and may address burnout for gynecologic oncology clinicians.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07282158
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Behavioral Intervention
Trials testing the same drug.
- NCT07377006 — Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer · NA · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07202247 — Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabol · Phase 2 · recruiting
- NCT06904391 — Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COA · NA · recruiting
- NCT06941324 — Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors · NA · recruiting
Other recruiting trials for Ovarian Carcinoma
Currently open trials in the same condition.
- NCT07280312 — Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions · NA · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06964009 — DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer · Phase 1 · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
Other Fred Hutchinson Cancer Center trials
Trials by the same sponsor.
- NCT07390968 — Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Pati · Phase 2 · not yet recruiting
- NCT07493252 — A Behavioral Application for Improving Smoking Cessation Among Smokers · NA · not yet recruiting
- NCT07490860 — A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to · NA · not yet recruiting
- NCT07194980 — Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small L · Phase 2 · not yet recruiting
- NCT07176000 — Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington S · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07282158 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fred Hutchinson Cancer Center
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07282158.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing